Submissions are only possible through online submission services.
The submission deadline is Thursday 7 December 2023, 12:00 noon CET.
Changes and corrections
Once submitted, it will not be possible to make any corrections to the content or other information (such as presenter details, topic, etc.). In order to correct your submission, you must withdraw it and submit a new version prior to the deadline (see below for the withdrawal procedure). Note that such a replacement of your submission is not possible after the submission deadline.
There is no limit to the number of tracing applications an author may submit, but you should not submit the same research twice. If you submit two applications with the same content, the submission service will automatically keep the most recent one and withdraw the other.
Withdrawal
If you want to withdraw your submission, please notify us as quickly as possible at ehra-congressscientific@escardio.org stating the title of your submission to be withdrawn. Note that withdrawal is still possible after the submission deadline.
Category of submission
Please select one of the following categories of submission under which your research can be best classified:
- Surface ECGs,
- Intracardiac electrograms (electrophysiology),
- Intracardiac electrograms (cardiac implantable devices).
Submission content structure
- Use the EHRA Call for tracings template
- Provide high-quality images of the tracings (min resolution 150 dpi)
- Provide 1-3 images per submission (more than one tracing can only be submitted if it is not possible to explain one without the other).
- 1 question with multiple choice answers must be inserted in your submission - the question should be direct, unambiguous and should address a single issue. Additionally, provide explanation to accompany correct answer (please follow the template structure).
- Tracings do not have to be very complex but must have high educational value.
- Provide minimal clinical information that is necessary to understand the tracing (<50 words).
- Provide at least one “take-home message” for your submission.
Important:
- As the grading and selection process is blind, the tracing title and PPT submitted must not contain identifying features, such as the name of the authors or the institution both in the text and on the images.
- As a submitter, you are responsible for removing any elements that could be used to identify patients. See the Patient consent and confidentiality paragraph in the submission rules and guidelines.
Failure to comply with the above requirements will lead to an automatic rejection of the submission.
Policies
Submission of an application constitutes a formal commitment by the author(s) to present the work in person in Berlin if accepted. Failure to present, upload the presentation by the deadline and register for the meeting will lead to the withdrawal of the research by the set deadlines.
All expenses (registration, airfare, hotel….) associated with the submission and presentation of a tracing, are under the responsibility of the presenter.
Results announcement
After the submission deadline, the system will be closed, and submissions will be forwarded to the Reviewing Committee. Changes or corrections will not be possible after the deadline.
The final selection will be made by a dedicated committee consisting of senior and junior electrophysiologists in January 2023. The Selection Committee will determine the format, day and time of presentation. No rescheduling or changes will be possible.
An email message will be sent to the submitter by the end of January 2023 with a report on the status of their submission (accepted or rejected).
If the submitted tracing is accepted, notification and further instructions concerning the presentation format will be sent directly to the submitter.
Authors' list
Please note that the first submitter will be considered as the first author and will be the presenter by default. Nevertheless, it can be modified by notification to the team at ehra-congressscientific@escardio.org. In all cases, the presenter must be part of the authors' list included in the submission and be able to explain his/her role in the research during the presentation.
Please make sure you have entered the full list of authors and that the information given for each author is correct.
Patient confidentiality and consent
It is the author's responsibility to ensure that:
- They have obtained all necessary consent(s), approvals and authorizations in connection with the submission to the ESC with the patient and any organization involved (Hospital, Clinic ...)
- Patient data (name, date of birth, hospital number…..) must be removed.
- All the content of the submission, including the text, its title and media files have been stripped of all personal information that could be used to identify the patient.
The author (s) are responsible to obtain an official patient’s consent for publication for educational purposes and for social media educational campaigns. In case the patient does not give full consent (including the social media acceptance), the submission can not be accepted.
Authors must be able to provide a copy of the written patient consent and any other related authorization upon request.
Data Privacy
By certifying that you have read these Submission rules, you also confirm having received prior approval from the co-authors to provide their data to the ESC. The information collected in this CALL FOR TRACINGS is subject to the data processing to proceed with the elaboration of the EHRA2024 Scientific programme. It is a statutory requirement to list the authors who have contributed to the research submitted. Authors not listed in the submission will not be acknowledged in the abstract if accepted for publication and presentation at the Congress and in the promotion of the abstract. The recipients of the data are ESC Staff who process the submissions and the ESC Committees and volunteers involved in the abstract programme. Data collected will be kept for 20 years. Transfer of personal data to ESC Staff, contractors as well as other ESC-related scientific organisations occur for the production, promotion and dissemination of the Congress Content. In accordance with chapter 3 of the European Regulation 2016/679 with regards to data protection, you have the right to request from ESC, access to and rectification or erasure of your personal data or restriction of processing concerning your data or to object to the processing as well as the right to data portability. This is done through the withdrawal of the abstract according to the terms and conditions of withdrawal.
For data privacy concerns, please contact (Kindly note that proof of identity will be required during the process through a secured link) -
Data Privacy - European Society of Cardiology
Les Templiers
2035 Route des Colles
CS 80179 Biot
06903 SOPHIA ANTIPOLIS CEDEX, France
Or by email to dataprivacy@escardio.org
You have the right to lodge a complaint with a supervisory authority, and for information, ESC has appointed a Data Protection Officer that you can reach at dpo@escardio.org
Applicable law
All the rules pertaining to the present submission rules are governed by, and construed in accordance with, the laws of France without regard to any conflicts of law principles thereof that would require the application of the law of any other jurisdiction. Any disputes arising in relation hereto shall be submitted to the exclusive jurisdiction of the French Tribunal Judiciaire located in Grasse, France.
The ESC reserves the right to make changes to the Tracings submission rules based on the Covid-19 situation and convention centre restrictions/protocols/requirements; and/or in case of exceptional/Force Majeure events (defined as unforeseeable and irresistible events beyond the control of the ESC, such as natural disasters, war, civil unrest, coup d'Etat….). Any update or change will be posted on the ESC website.
If you have difficulties in submitting your tracing(s) or if you need any further information, please contact us at ehra-congressscientific@escardio.org
Our mission: To reduce the burden of cardiovascular disease.